ArticleTranslational vision science & technology2018
Automated Method of Grading Vitreous Haze in Patients With Uveitis for Clinical Trials.
Article in Translational vision science & technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03889860 (Objective Choroidal Thickness Measurements During Intraocular Inflammation in Uveitis Using Optical Coherence Tomography), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Objective Choroidal Thickness Measurements During Intraocular Inflammation in Uveitis Using Optical Coherence Tomography
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Noninvasive Instrument-based Tests for Detecting and Measuring Vitreous Inflammation in Uveitis: A Systematic Review.Ocular immunology and inflammation · 2022Pooled it
- Qualitative and Quantitative Assessment of Vitreous Inflammation in Uveitis: Current Limitations and Emerging Diagnostic Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- The expanding horizon: Role of widefield imaging in uveitis.Indian journal of ophthalmology · 2026Review
- Diagnosis of Chronic Kidney Disease Using Retinal Imaging and Urine Dipstick Data: Multimodal Deep Learning Approach.JMIR medical informatics · 2025Article
- Artificial Intelligence in Uveitis: Innovations in Diagnosis and Therapeutic Strategies.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Diagnosis, Classification, and Assessment of the Underlying Etiology of Uveitis by Artificial Intelligence: A Systematic Review.Journal of clinical medicine · 2023Review
- Quantitative Assessment of Experimental Ocular Inflammatory Disease.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUveitis is associated with accumulation of exudate in the vitreous, which reduces fundus visibility. The condition is assessed in patients by subjectively matching fundus photographs to a six-level (NIH) or nine-level (Miami) haze scale. This study aimed to develop an objective method of assessing vitreous haze.
methodsAn image-processing algorithm was designed that quantifies vitreous haze via high-pass filtering, entropy analysis, and power spectrum integration. The algorithm was refined using nine published photographs that represent incremental levels of fundus blur and applied without further refinement to 120 random fundus photographs from a uveitis image library. Computed scores were compared against the grades of two trained readers of vitreous haze and against acutance, a generic measure of image clarity, using Cohen's
resultsExact agreement between algorithm scores and reader grades was substantial for both NIH and Miami scales (
conclusionsThe computer algorithm produces a quantitative measure of vitreous haze that correlates strongly with the perception of expert graders. TRANSLATIONAL RELEVANCE: The work offers a rapid, unbiased, standardized means of assessing vitreous haze for clinical and telemedical monitoring of uveitis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.